Literature DB >> 15334547

Various types of rearrangements target TLX3 locus in T-cell acute lymphoblastic leukemia.

Xin Ying Su1, Maryvonne Busson, Véronique Della Valle, Paola Ballerini, Nicole Dastugue, Pascaline Talmant, Adolfo A Ferrando, Dominique Baudry-Bluteau, Serge Romana, Roland Berger, Olivier A Bernard.   

Abstract

Most chromosomal translocations observed in T-cell acute lymphoblastic leukemia (T-ALL) often produce transcriptional activation of transcription factor oncogenes. Ectopic expression of the TLX3 (also known as HOX11L2) gene has been shown to be associated with a cryptic t(5;14)(q35;q32) translocation specific for a subtype of T-ALL. Here we report several examples of variant and alternative translocations resulting in expression of TLX3 in T-ALL, and we describe three of these translocations in detail. In particular, the CDK6 gene was rearranged in two t(5;7)(q35;q21) translocations. In two additional instances, fusion of the BCL11B (also known as CTIP2) and RANBP17/TLX3 loci were shown to result from subtle genomic insertion/deletion within these loci. This study further underscores that TLX3 expression in T-ALL is strongly associated with the presence of genomic rearrangements. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334547     DOI: 10.1002/gcc.20088

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

Review 1.  T-cell acute lymphoblastic leukemia.

Authors:  Sabina Chiaretti; Robin Foà
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

2.  CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks.

Authors:  Iris Z Uras; Barbara Maurer; Harini Nivarthi; Philipp Jodl; Karoline Kollmann; Michaela Prchal-Murphy; Jelena D Milosevic Feenstra; Markus Zojer; Sabine Lagger; Reinhard Grausenburger; Beatrice Grabner; Raimund Holly; Anoop Kavirayani; Christoph Bock; Heinz Gisslinger; Peter Valent; Robert Kralovics; Veronika Sexl
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

3.  A far downstream enhancer for murine Bcl11b controls its T-cell specific expression.

Authors:  Long Li; Jingli A Zhang; Marei Dose; Hao Yuan Kueh; Ruzbeh Mosadeghi; Fotini Gounari; Ellen V Rothenberg
Journal:  Blood       Date:  2013-06-05       Impact factor: 22.113

4.  CTIP2 associates with the NuRD complex on the promoter of p57KIP2, a newly identified CTIP2 target gene.

Authors:  Acharawan Topark-Ngarm; Olga Golonzhka; Valerie J Peterson; Brian Barrett; Brigetta Martinez; Kristi Crofoot; Theresa M Filtz; Mark Leid
Journal:  J Biol Chem       Date:  2006-09-01       Impact factor: 5.157

5.  Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.

Authors:  Iris Z Uras; Gina J Walter; Ruth Scheicher; Florian Bellutti; Michaela Prchal-Murphy; Anca S Tigan; Peter Valent; Florian H Heidel; Stefan Kubicek; Claudia Scholl; Stefan Fröhling; Veronika Sexl
Journal:  Blood       Date:  2016-04-20       Impact factor: 22.113

6.  14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia.

Authors:  Danika Di Giacomo; Roberta La Starza; Paolo Gorello; Fabrizia Pellanera; Zeynep Kalender Atak; Kim De Keersmaecker; Valentina Pierini; Christine J Harrison; Silvia Arniani; Martina Moretti; Nicoletta Testoni; Giovanna De Santis; Giovanni Roti; Caterina Matteucci; Renato Bassan; Peter Vandenberghe; Stein Aerts; Jan Cools; Beat Bornhauser; Jean-Pierre Bourquin; Rocco Piazza; Cristina Mecucci
Journal:  Blood       Date:  2021-09-02       Impact factor: 22.113

7.  Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.

Authors:  Giusy Della Gatta; Teresa Palomero; Arianne Perez-Garcia; Alberto Ambesi-Impiombato; Mukesh Bansal; Zachary W Carpenter; Kim De Keersmaecker; Xavier Sole; Luyao Xu; Elisabeth Paietta; Janis Racevskis; Peter H Wiernik; Jacob M Rowe; Jules P Meijerink; Andrea Califano; Adolfo A Ferrando
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

Review 8.  CDK6 Inhibition: A Novel Approach in AML Management.

Authors:  Iris Z Uras; Veronika Sexl; Karoline Kollmann
Journal:  Int J Mol Sci       Date:  2020-04-05       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.